Humana (NYSE:HUM) Price Target Raised to $495.00

Humana (NYSE:HUM) had its price objective hoisted by Mizuho from $468.00 to $495.00 in a research note released on Tuesday morning, Marketbeat reports. Mizuho currently has an outperform rating on the insurance provider’s stock.

HUM has been the subject of a number of other research reports. Guggenheim lifted their target price on Humana from $269.00 to $471.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Wolfe Research reiterated an “outperform” rating and issued a $450.00 price target on shares of Humana in a report on Monday, August 24th. Royal Bank Of Canada increased their price target on shares of Humana from $246.00 to $415.00 and gave the stock a “sector perform” rating in a report on Thursday, July 9th. Piper Sandler raised shares of Humana from a “hold” rating to an “overweight” rating and set a $463.00 price target for the company in a research report on Thursday, July 30th. Finally, Morgan Stanley raised shares of Humana from an “underweight” rating to an “overweight” rating in a research report on Friday, October 9th. Twenty-one analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Humana currently has an average rating of “Moderate Buy” and a consensus price target of $453.30.

Humana Price Performance

Shares of HUM opened at $431.99 on Tuesday. The firm has a market capitalization of $51.87 billion, a PE ratio of 24.85, a price-to-earnings-growth ratio of 2.63 and a beta of 0.74. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74. Humana has a 1-year low of $163.11 and a 1-year high of $456.50. The company’s fifty day moving average price is $393.53 and its 200-day moving average price is $341.92.

Humana (NYSE:HUM) last released its earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.27 by $0.34. The firm had revenue of $40.89 billion for the quarter, compared to the consensus estimate of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%. The firm’s revenue was up 26.2% on a year-over-year basis. During the same period in the prior year, the firm earned $6.27 EPS. On average, equities research analysts predict that Humana will post 9.03 EPS for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, November 27th. Shareholders of record on Friday, October 30th will be issued a $0.8850 dividend. The ex-dividend date of this dividend is Friday, October 30th. This represents a $3.54 dividend on an annualized basis and a yield of 0.8%. Humana’s payout ratio is presently 33.49%.

Institutional Investors Weigh In On Humana

Several hedge funds have recently bought and sold shares of HUM. BlackRock Inc. purchased a new position in shares of Humana during the 2nd quarter valued at approximately $4,138,160,000. Pzena Investment Management LLC purchased a new stake in Humana during the second quarter worth $1,749,014,000. Assenagon Asset Management S.A. boosted its holdings in Humana by 20,126.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider’s stock worth $479,053,000 after buying an additional 1,249,272 shares in the last quarter. Legal & General Group Plc purchased a new stake in Humana during the second quarter worth $329,760,000. Finally, Barrow Hanley Mewhinney & Strauss LLC acquired a new stake in Humana during the second quarter valued at $314,922,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana News Roundup

Here are the key news stories impacting Humana this week:

• Positive Sentiment: BlackRock partnership provides substantial capital: BlackRock is reportedly investing approximately $2.8 billion for a majority stake in nearly 150 CenterWell senior primary-care clinics. The transaction should reduce Humana’s capital burden, improve liquidity and help fund CenterWell’s expansion while allowing Humana to retain an economic interest. BlackRock to buy majority stake in Humana’s CenterWell clinics for $2.8 billion
• Positive Sentiment: CenterWell growth prospects strengthened: The joint venture is expected to support the rollout and development of additional senior-care clinics, reinforcing Humana’s strategy of expanding primary-care delivery for older adults. Humana’s CenterWell Expansion Gets a Boost From BlackRock’s Capital
• Positive Sentiment: Analyst support: A Mizuho analyst reportedly expects Humana’s stock to rise, adding to the favorable sentiment surrounding the company’s strategic initiatives. Humana Stock Price Expected to Rise, Mizuho Analyst Says
• Neutral Sentiment: Humana announced or received attention for a Medicare Advantage coverage policy expanding access to AngioDynamics’ NanoKnife cancer treatment. The move may enhance member benefits and care options, but its direct financial impact appears limited. AngioDynamics Announces Humana Medicare Advantage Coverage Policy
• Negative Sentiment: 2027 plan exits could create disruption: Humana plans to discontinue 37 PPO plans for 2027. Although affected members may have a time-limited right to enroll in Medigap without medical underwriting, plan exits could lead to member attrition, regulatory scrutiny and transition costs. Humana Will Drop 37 PPOs for 2027

Humana Company Profile

Humana Inc is a health and well-being company headquartered in Louisville, Kentucky. Founded in 1961, the company began as a nursing home operator before expanding into hospitals and health insurance. Today, Humana primarily provides health insurance products and healthcare services for older adults, individuals, military families and other members in the United States.

Humana’s insurance business offers Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid coverage in select markets.